Compare ARK Genomic Revolution ETF (ARKG) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs PepsiCo, Inc. — how do they compare? ARK Genomic Revolution ETF trades at $40.83, while PepsiCo, Inc. trades at $137.76 (market cap $187.51B). The key difference: PepsiCo, Inc. pays a 4.31% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, PepsiCo, Inc. nearer its low. Which is the better fit depends on your goals.
| ARKG | PEP | |
|---|---|---|
Sector | Sector/Thematic | Consumer Staples |
52-Week High | $43.57 | $170.44 |
52-Week Low | $23.09 | $133.81 |
Market Cap | — | $187.51B |
Enterprise Value | — | $230.01B |
Dividend Yield | — | 4.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
PepsiCo (PEP) trades at $137.38, down 0.35% on the day, with technical indicators signaling a bearish trend amid neutral oscillators. The company reported revenue of $93.93B for 2025 with a net income margin of 10.78%, while recent earnings beats and a forward dividend yield near 4% provide fundamental support. News highlights include price cuts on snacks after consumer pushback and the withdrawal from a controversial music festival sponsorship.
The outlook remains cautious with Wall Street consensus leaning Hold (64% of analysts) but a price target of $159.27 suggests 16% upside. Key risks include execution of North American turnaround and margin pressure from inflation, though institutional buying activity indicates underlying confidence in the long-term strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
